FDA authorizes limited prescriptions of Paxlovid by pharmacists

Jul 06, 2022 - 04:05 PM
FDA-update-generic-drugs

The Food and Drug Administration today authorized state-licensed pharmacists to prescribe Paxlovid (nirmatrelvir and ritonavir) to patients as a treatment for those at high risk of severe COVID-19. Because Paxlovid must be taken within five days of symptom onset, the change could spur expanded access and more-timely treatment of eligible patients. The change was made through an amended emergency use authorization. 

Related News Articles

Headline
FDA issues guidance on wellness products, clinical decision support software
The Food and Drug Administration today released two guidance documents; one related to low-risk wellness products (including certain wearable devices) and the…
Headline
CDC adopts ACIP recommendation for hepatitis B vaccine at birth
The Centers for Disease Control and Prevention announced Dec. 16 that it adopted individual-based decision-making for parents deciding whether to give the…
Headline
CDC report finds COVID-19 vaccine for children reduced chances of ED, urgent care visits
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
CDC releases advisory on Marburg virus outbreak in Ethiopia; ASPR to provide support 
The Centers for Disease Control and Prevention issued an advisory Dec. 3 on an outbreak of Marburg virus in Ethiopia. The agency said a risk of spread to the U…
Headline
AHA responds to FDA request for information on AI-enabled medical devices
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
Permanent recall issued for Baxter ventilation system
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…